AnaptysBio, Inc.
ANAB
$65.03
$0.310.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 228.29% | 139.12% | 1.78% | -80.54% | 33.69% |
| Total Depreciation and Amortization | -0.66% | 1.50% | -0.83% | 0.83% | 0.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.73% | 12.09% | 6.59% | 9.78% | 10.70% |
| Change in Net Operating Assets | 127.03% | -149.88% | -1,298.17% | 103.58% | -6,191.67% |
| Cash from Operations | 458.23% | 32.02% | -276.11% | 83.95% | -560.77% |
| Capital Expenditure | 91.67% | 69.23% | -11.43% | 86.69% | -651.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -28.84% | 183.45% | 144.87% | 151.08% | -149.67% |
| Cash from Investing | -28.84% | 183.72% | 145.19% | 150.51% | -150.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,534.52% | -76.39% | 390.69% | -47.75% | -99.44% |
| Repurchase of Common Stock | 65.19% | 80.98% | -1,055.02% | -870.18% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5,060.08% | -22.36% | 96.63% | -189.03% | 200.74% |
| Cash from Financing | -315.11% | 79.42% | -76.63% | -203.71% | -61.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.87% | 220.60% | -122.31% | 64.32% | -157.20% |